SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021)

Thymic epithelial tumours (TET) represent a heterogeneous group of rare malignancies that include thymomas and thymic carcinoma. Treatment of TET is based on the resectability of the tumour. If this is considered achievable upfront, surgical resection is the cornerstone of treatment. Platinum-based...

Descripción completa

Detalles Bibliográficos
Autores: Remon, Jordi|||0000-0002-9462-875X, Bernabé, Reyes|||0000-0003-0312-9195, Diz Taín, Pilar|||0000-0003-4284-3965, Felip, Enriqueta|||0000-0002-7620-0098, González Larriba, José Luis|||0000-0003-2631-0309, Lázaro, Martín|||0000-0002-0657-4713, Mielgo-Rubio, Xabier|||0000-0002-0985-6150, Sánchez Hernández, Alfredo|||0000-0001-5826-8390, Sullivan, Ivana|||0000-0002-0434-3436, Massuti, Bartomeu|||0000-0002-6247-4493
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:286317
Acceso en línea:https://ddd.uab.cat/record/286317
https://dx.doi.org/urn:doi:10.1007/s12094-022-02788-w
Access Level:acceso abierto
Palabra clave:Chemotherapy
Lenvatinib
Multidisciplinary
Nivolumab
Thymic epithelial tumours
Descripción
Sumario:Thymic epithelial tumours (TET) represent a heterogeneous group of rare malignancies that include thymomas and thymic carcinoma. Treatment of TET is based on the resectability of the tumour. If this is considered achievable upfront, surgical resection is the cornerstone of treatment. Platinum-based chemotherapy is the standard regimen for advanced TET. Due to the rarity of this disease, treatment decisions should be discussed in specific multidisciplinary tumour boards, and there are few prospective clinical studies with new strategies. However, several pathways involved in TET have been explored as potential targets for new therapies in previously treated patients, such as multi-tyrosine kinase inhibitors with antiangiogenic properties and immune checkpoint inhibitors (ICI). One third of patient with thymoma present an autoimmune disorders, increasing the risk of immune-related adverse events and autoimmune flares under ICIs. In these guidelines, we summarize the current evidence for the therapeutic approach in patients with TET and define levels of evidence for these decisions.

Similares en LA Referencia